Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Erweiterte Suche bearbeiten
Filter bei nächster Suche beibehalten
topic_facet:"Letter"
topic_facet:"Antibodies, Monoclonal, Humanized"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Letter%22&filter%5B%5D=topic_facet%3A%22Antibodies%2C+Monoclonal%2C+Humanized%22&join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=%221365-2036%22&type0%5B%5D=ISN&op0%5B%5D=OR
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Letter%22&filter%5B%5D=topic_facet%3A%22Antibodies%2C+Monoclonal%2C+Humanized%22&join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=%221365-2036%22&type0%5B%5D=ISN&op0%5B%5D=OR
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Letter%22&filter%5B%5D=topic_facet%3A%22Antibodies%2C+Monoclonal%2C+Humanized%22&join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=%221365-2036%22&type0%5B%5D=ISN&op0%5B%5D=OR
PubPharm (50)
1
Letter : Comparing first-line infliximab and vedolizumab for ulcerative colitis-it depends on how you use the drug. Authors' reply
enthalten in:
Alimentary pharmacology & therapeutics
| 2024
von
Bokemeyer, B.
|
Plachta-Danielzik, S.
Wird geladen...
2
Letter : Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis
enthalten in:
Alimentary pharmacology & therapeutics
| 2023
von
Chang, H.
|
Gau, S.
CommentOn: Aliment Pharmacol Ther. 2023 Aug;58(3):297-308. - PMID 37300328
Wird geladen...
3
Letter : Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis-Authors' reply
enthalten in:
Alimentary pharmacology & therapeutics
| 2023
von
Desai, A.
|
Regueiro, M.
|
Kochhar, G.
CommentOn: Aliment Pharmacol Ther. 2023 Dec;58(11-12):1242. - PMID 37986597
Wird geladen...
4
Letter : Experience of switching vedolizumab treatment from intravenous to subcutaneous formulation in Hungary
enthalten in:
Alimentary pharmacology & therapeutics
| 2023
von
Bacsur, P.
|
Iliás, .
|
Resál, T.
| +3
CommentOn: Aliment Pharmacol Ther. 2022 Sep;56(6):1044-1054. - PMID 35869807
Wird geladen...
5
Letter : tricky reactions to switch back from subcutaneous to intravenous vedolizumab in patients with inflammatory bowel disease
enthalten in:
Alimentary pharmacology & therapeutics
| 2023
von
Richard, N.
|
Vuitton, L.
|
Fumery, M.
CommentOn: Aliment Pharmacol Ther. 2022 Sep;56(6):1044-1054. - PMID 35869807
Wird geladen...
6
Letter : tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients-authors' reply
enthalten in:
Alimentary pharmacology & therapeutics
| 2023
von
Volkers, A.
|
Straatmijer, T.
|
Duijvestein, M.
| +3
CommentOn: Aliment Pharmacol Ther. 2022 Sep;56(6):1044-1054. - PMID 35869807
Wird geladen...
7
Letter : potential selection bias in the real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease
enthalten in:
Alimentary pharmacology & therapeutics
| 2022
von
Adomi, M.
|
Ray, A.
CommentOn: Aliment Pharmacol Ther. 2022 Apr;55(7):856-866. - PMID 34935160
Wird geladen...
8
Letter : potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply
enthalten in:
Alimentary pharmacology & therapeutics
| 2022
von
Selinger, C.
|
Lenti, M.
|
De Silvestri, A.
CommentOn: Aliment Pharmacol Ther. 2022 Apr;55(7):856-866. - PMID 34935160
Wird geladen...
9
Letter : vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply
enthalten in:
Alimentary pharmacology & therapeutics
| 2021
von
Rundquist, S.
|
Sachs, M.
|
Eriksson, C.
| +3
CommentOn: Aliment Pharmacol Ther. 2021 Feb;53(4):471-483. - PMID 33340426
Wird geladen...
10
Letter : vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD
enthalten in:
Alimentary pharmacology & therapeutics
| 2021
von
Demarzo, M.
|
Bodini, G.
|
Vanello, M.
| +2
CommentOn: Aliment Pharmacol Ther. 2021 Feb;53(4):471-483. - PMID 33340426
Wird geladen...
1
2
3
4
5
Nächster »
[5]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: Letter
Filter aufheben
Thema: Antibodies, Monoclonal, Humanized
Medienart
50
Aufsätze
50
E-Artikel
50
E-Ressourcen
Zeitschriftentitel
50
Alimentary pharmacology & therapeutics
Thema
Antibodies, Monoclonal, Humanized
Letter
48
Comment
30
9RV78Q2002
30
vedolizumab
20
Tumor Necrosis Factor-alpha
15
FU77B4U5Z0
15
Ustekinumab
14
Antibodies, Monoclonal
10
Immunosuppressive Agents
7
B72HH48FLU
7
Infliximab
6
Adalimumab
6
Anti-Inflammatory Agents
6
FYS6T7F842
5
3WJQ0SDW1A
5
Immunoglobulin Fab Fragments
5
Polyethylene Glycols
5
Research Support, Non-U.S. Gov't
3
Gastrointestinal Agents
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
22
2020-
27
2010-2019
1
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
50
Englisch
Haven't found what you're looking for?
Wird geladen...